天津市依依卫生用品股份有限公司 第四届董事会第五次会议决议公告 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：001206 证券简称：依依股份 公告编号：2026-011 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 本议案不涉及关联交易，无需回避表决。 4、提交股东会表决情况： 天津市依依卫生用品股份有限公司（以下简称"公司"）第四届董事会第五次会议通知已于2026年1月28 日通过电话、邮件方式送达。会议于2026年2月2日以现场表决结合通讯表决的方式在公司会议室召开。 本次会议应出席董事14名，实际出席董事14名，其中独立董事何勇军先生、韦祎先生、肖和勇先生、刘 颖女士以通讯方式出席。会议由董事长高福忠先生主持，公司全部高级管理人员列席了会议。本次会议 的召开和表决程序符合《中华人民共和国公司法》等法律、法规、规范性文件和《天津市依依卫生用品 股份有限公司章程》的有关规定，会议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于调整回购股份价格上限的议案》 1、议案内容 鉴于公司股价近期持续高于公司回购股份方 ...

Core Viewpoint - Recent adjustments by major banks in China, including China Agricultural Bank, China Merchants Bank, and Bank of China, are aimed at mitigating risks associated with significant fluctuations in precious metal prices, emphasizing the need for investors to manage their positions and invest rationally [1][2][5]. Group 1: Bank Adjustments - China Merchants Bank announced an increase in margin requirements for various gold contracts from 60% to 70% due to heightened volatility in precious metal prices, while maintaining a 15% limit on price fluctuations [1]. - Bank of China adjusted the margin for silver deferred contracts from 50.80% to 66.04% and increased the fluctuation limit from 19% to 25% if a unilateral market condition occurs [5]. - Agricultural Bank of China also indicated adjustments to the fluctuation limits for silver contracts, aligning with the Shanghai Gold Exchange's risk management guidelines [7]. Group 2: Market Implications - Industry experts suggest that these measures are intended to tighten risk controls, reduce trading leverage, and increase capital costs for investors, thereby curbing speculative behavior in the market [2][7]. - The adjustments are expected to enhance liquidity during extreme market conditions and reduce the probability of defaults, with other banks likely to follow suit in implementing similar risk management strategies [7]. - Banks are advising investors to carefully assess their risk tolerance and financial situation, urging a rational investment approach and close monitoring of market conditions to mitigate potential losses from price volatility [9][10].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 山东南山铝业股份有限公司（以下简称"公司"）于2026年1月22日发布了《山东南山铝业股份有限公司 关于控股子公司南山铝业国际控股有限公司根据一般性授权配售股份的公告》（公告编号：2026-008， 以下简称"配售公告"），内容有关公司控股子公司南山铝业国际控股有限公司（以下简称"南山铝业国 际"）与南山铝业全资子公司Nanshan Aluminium Investment Holding Limited、2名配售代理签订配售协议 及根据配售协议进行港股配售（以下简称"本次配售"）。 公司获悉，本次配售已于2026年1月30日完成，南山铝业国际按64.50港元/股的配售价格向不少于6名的 承配人通过"先旧后新"方式配售合计31,000,000股，配售所得款项净额约为 19.87 亿港元，资金用途见 配售公告披露内容。 本次配售完成后，南山铝业国际的股份总数为620,435,200股，其中公司全资子公司Nanshan Aluminium Investment Holding L ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 青海互助天佑德青稞酒股份有限公司（以下简称"公司"）董事会于近日收到公司董事、总经理万国栋先 生的书面辞职报告，因个人原因，万国栋先生申请辞去公司董事、总经理、董事会战略与决策委员会委 员职务。万国栋先生辞职后不再在公司及其子公司担任任何职务。 截至本公告日，万国栋先生持有公司股份455,000股。辞去公司董事、总经理职务后，万国栋先生将继 续履行相关承诺并遵守《证券法》和《公司章程》等相关法律法规的规定，对所持公司股份进行管理。 公司及公司董事会对万国栋先生在任职期间对公司做出的努力表示感谢！ 特此公告。 青海互助天佑德青稞酒股份有限公司董事会 2026年2月1日 根据《公司法》《深圳证券交易所上市公司自律监管指引第1号一一主板上市公司规范运作（2025年修 订）》等法律法规以及《公司章程》的相关规定，万国栋先生的辞职报告自送达公司董事会之日起生 效，万国栋先生的辞职未导致公司董事会成员人数低于法定人数，不会对公司董事会运作产生影响。公 司后续将按照法定程序尽快 ...

Core Viewpoint - The company, Shanghai Yizhong Pharmaceutical Co., Ltd., has initiated a share repurchase program to maintain company value and protect shareholder interests, with plans to sell the repurchased shares within a specified timeframe [2][3]. Group 1: Share Repurchase Details - The company repurchased a total of 1,274,307 shares from August 26, 2024, to December 25, 2024 [2]. - The repurchased shares will be sold through centralized bidding within twelve months after the announcement of the repurchase results, and any unsold shares will be canceled [2]. Group 2: Sale Plan Progress - The company plans to sell up to 1,274,307 repurchased shares, not exceeding 0.62% of the total share capital, within six months from January 22, 2026, to July 21, 2026 [3]. - Proceeds from the sale will be used to supplement the company's working capital to support research and development projects and daily operations [3]. Group 3: Implementation Status - As of January 31, 2026, the company has not yet sold any of the repurchased shares [4]. - The company is required to disclose the progress of the sale plan within the first three trading days of each month [6]. Group 4: Compliance and Regulations - The sale plan is consistent with previously disclosed plans and complies with relevant regulations, including the Shanghai Stock Exchange's guidelines on share repurchase [6]. - The company will adhere to legal requirements during the sale process and fulfill information disclosure obligations [8].

Core Viewpoint - The company has completed the enrollment of 100 subjects for the Phase II/III clinical trial of Huperzine A Controlled-Release Tablets, a new drug for treating mild to moderate Alzheimer's disease, indicating progress in its drug development efforts [1][3]. Group 1: Product Information - Product Name: Huperzine A Controlled-Release Tablets - Drug Classification: Category 2.2 new drug - Indication: Mild to moderate Alzheimer's disease - Dosage Form: Tablet, 0.2mg [1][2] - The drug is a cholinesterase inhibitor aimed at improving cognitive function, showing potential in preclinical studies to slow the progression of Alzheimer's disease and offering various benefits, including reducing β-amyloid protein, anti-inflammatory, antioxidant stress, and neuroprotective effects [1]. Group 2: Clinical Trial Details - The company is collaborating with over 50 research institutions nationwide, including Capital Medical University Xuanwu Hospital, to further validate the drug's safety and efficacy [3]. - The controlled-release technology allows for a smoother drug release profile, enhancing patient convenience and adherence by supporting once-daily dosing [2].

Group 1 - The company's stock price experienced an abnormal fluctuation, with a cumulative increase of over 20% from January 28 to January 30, 2026, which is classified as an abnormal trading situation according to Shenzhen Stock Exchange regulations [1] - The company conducted an internal review and confirmed that there were no corrections or supplements needed for previously disclosed information [2] - The company did not find any significant undisclosed information in public media that could have impacted the stock price [2] Group 2 - The company confirmed that there were no major changes in its operational situation or external business environment that could affect its performance [2] - The company and its controlling shareholder did not engage in any trading of the company's stock during the period of abnormal fluctuation [2] - The board of directors affirmed that there are no undisclosed matters that should have been disclosed according to the Shenzhen Stock Exchange rules [3]

6 or 21 th 159 s E ■ ■▲, 图 88 10 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 三、中止审核对公司的影响及后续安排 公司于2026年1月31日收到上海证券交易所（以下简称"上交所"）审核通知：国旅文化投资集团股份有 限公司主板发行股份购买资产业务已中止审核。 一、本次中止审核的说明 公司本次交易引用的经审计的财务报表截止日为2025年4月30日。根据《公开发行证券的公司信息披露 内容与格式准则第26号一一上市公司重大资产重组》第六十九条规定，重组报告书经审计的最近一期财 务资料在财务报告截止日后六个月内有效，本次交易涉及发行股份的，特别情况下可适当延长，但延长 时间至多不超过三个月。公司本次交易重组报告书经审计财务数据于2026年1月31日过有效期。 2026年1月31日，公司收到上交所的通知，因本次交易申请文件中记载的财务资料已过有效期，需要补 充提交，按照《上海证券交易所上市公司重大资产重组审核规则》的有关规定，上交所对公司本次交易 事项中止审核。目前，财务数据更新工作尚在准备过程中。 二、本次交易的相关进展 公司于2025年9月19日收到上交所出具的《关于受理国旅文化投资集团股份有限公司发行股份购买资产 并募集配套资金申请的通知》（ ...

登录新浪财经APP 搜索【信披】查看更多考评等级 3、公司目前经营情况正常，内外部经营环境未发生重大变化； 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股票交易异常波动的情况介绍 甘肃皇台酒业股份有限公司（以下简称"公司"）股票于2026年1月29日、2026年1月30日连续两个交易日 收盘价格涨幅偏离值累计超过20%，根据《深圳证券交易所交易规则》的有关规定，属于股票交易异常 波动的情形。 二、公司关注并核实的情况 针对股票交易异常波动情况，公司已进行深入、全面的自查，并已与控股股东、实际控制人进行了核 实，现将有关情况说明如下： 1、截止本公告日，公司不存在应披露而未披露的信息，前期披露的信息不存在需要更正、补充之处； 2、经公司核实，公司未发现对公司股票交易价格可能产生重大影响的媒体报道或市场传闻，未涉及热 点概念事项，亦未发现其他可能对公司股票交易价格产生较大影响的重大事件； 4、公司、控股股东及实际控制人不存在关于公司应披露而未披露的重大事项，或处于筹划阶段的重大 事项； 5、股票异常波动期间，不存在控股股东、实际控制人、持股 5%以上股东以 ...